PreveCeutical Medical Inc (CSE:PREV, OTCMKTS:PRVCF) said Monday that it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments of epilepsy, anxiety and depression.
The gel spray is superior to conventional liquid sprays in delivering formulations into the upper nasal cavity, the Vancouver-based company said in a press release. PreveCeutical’s Sol-gels are delivered by using a device known as the So-gel Applicator.
"This is an important development for PreveCeutical, having demonstrated that its engineered Sol-gels and applicator device achieve delivery and retention directly at target tissue high in the nasal cavity,” Dr. Harendra Parekh, chief research officer, said in a statement.
The company said in August that it is developing a cannabinoid formulation for the treatment of patient anxiety.
In September, PreveCeutical struck a deal with Asterion Cannabis Inc to develop cannabis-based medical products.
Shares eased 5.26% to $0.09 in Toronto.